Effectively targeting intracellular tumor-associated proteins presents a formidable challenge in oncology, as they are traditionally considered inaccessible to conventional antibody-based therapies and CAR-T cell therapies. However, recent advancements in antibody engineering have revolutionized this field, offering promising new strategies to combat cancer. This review focuses on the innovative use of T-cell receptor mimic (TCRm) antibodies within the therapeutic frameworks of T-cell engagers (TCE) and antibody-drug conjugates (ADCs). TCRm antibodies, designed to recognize peptide-MHC complexes rather than cell surface proteins, integrate the capacity of T-cells to reach intracellular targets with the unique strengths of antibodies. When incorporated into T-cell engaging therapeutics, TCRms redirect T cells to cancer cells, facilitating direct cytotoxicity. In ADCs, TCRm antibodies deliver cytotoxic agents with highly specific targeting to cancer cells, sparing healthy tissues. Together, these antibody-based strategies represent a significant leap forward in oncology, opening new avenues for the treatment of cancers previously deemed untreatable, with other potential applications in autoimmune diseases. This review discusses the mechanisms, clinical advancements, and future prospects of these cutting-edge therapies, highlighting their potential to transform the landscape of cancer treatment.
有效靶向细胞内肿瘤相关蛋白是肿瘤学领域的一项重大挑战，因为这些蛋白传统上被认为无法通过常规抗体疗法和CAR-T细胞疗法进行干预。然而，近年来抗体工程技术的突破性进展为该领域带来了革命性变革，为癌症治疗提供了前景广阔的新策略。本综述聚焦于T细胞受体模拟抗体在T细胞衔接器疗法和抗体药物偶联物治疗框架中的创新应用。T细胞受体模拟抗体通过识别肽-MHC复合物而非细胞表面蛋白，将T细胞靶向细胞内抗原的能力与抗体的独特优势相结合。在T细胞衔接器疗法中，这类抗体能够重定向T细胞攻击癌细胞，实现直接细胞毒性杀伤；而在抗体药物偶联物中，它们可将细胞毒性药物精准递送至癌细胞，同时保护健康组织。这些基于抗体的治疗策略共同代表了肿瘤治疗领域的重大飞跃，为既往难以治疗的癌症开辟了新途径，并在自身免疫性疾病等领域展现出潜在应用前景。本综述系统探讨了这些前沿疗法的分子机制、临床进展与未来发展方向，着重阐释其改变癌症治疗格局的巨大潜力。
肿瘤(癌症)患者之家